Why do u get shingles

What It Is

Shingles is a painful viral infection caused by the reactivation of the varicella-zoster virus (VZV), the same pathogen responsible for chickenpox. The virus remains dormant in nerve tissue called dorsal root ganglia after a person recovers from chickenpox. When the virus reactivates, it causes inflammation of these nerve cells and travels along the nerve fibers to the skin, producing a characteristic painful rash. Shingles, also called herpes zoster, is not contagious from person to person, though the virus can spread to those who have never had chickenpox.

The history of shingles understanding dates back centuries, with descriptions appearing in ancient medical texts from Greece and Persia. In 1889, French neurologist Jean-Martin Charcot established the link between chickenpox and shingles, demonstrating that they were caused by the same pathogen. The varicella-zoster virus itself was first identified in 1953 by researchers at Baylor College of Medicine. The development of the varicella vaccine in 1995 and the more effective Shingrix vaccine in 2017 has changed prevention strategies significantly.

Shingles manifestations include the early stage with pain, itching, and burning along a nerve path; the active stage with fluid-filled blisters arranged in bands or clusters; and the crusting stage as blisters dry and form scabs. Another category includes ophthalmic shingles, affecting the eye and potentially causing vision problems, and disseminated shingles, where the rash spreads widely across the body in immunocompromised individuals. Shingles can also affect cranial and spinal nerves, causing complications like facial paralysis (Ramsay Hunt syndrome) or weakness in limbs.

How It Works

The pathophysiology of shingles involves viral reactivation and nerve inflammation triggered by declining cell-mediated immunity. During chickenpox infection, the immune system initially controls the virus but doesn't eliminate it completely; VZV remains latent in nerve cell bodies. When immune function declines due to aging, stress, illness, or immunosuppressive therapy, the virus escapes immune surveillance and begins replicating within the nerve cells. This viral replication causes inflammation, damage to nerve fibers, and leads to the characteristic unilateral (one-sided) rash following the distribution of a single spinal or cranial nerve.

A practical example of shingles development occurs in a 65-year-old retired teacher who experiences extreme stress after losing a spouse, followed by severe fatigue and a burning pain along the right side of the ribs two weeks later, progressing to a blistering rash over several days. Another example involves a 72-year-old cancer patient undergoing chemotherapy who develops shingles on the left forehead and upper eyelid, requiring emergency ophthalmology consultation to prevent vision loss. A third example includes a 55-year-old kidney transplant recipient taking immunosuppressive medications who develops disseminated shingles affecting multiple body areas, requiring hospitalization and intravenous antiviral therapy. These cases demonstrate how varying risk factors lead to shingles manifestation.

The step-by-step progression involves viral reactivation in dorsal root ganglia, followed by viral spread along axons toward the skin (centrifugal spread), causing pain and paraesthesia before the rash appears. As the virus reaches the epidermis, it triggers the inflammatory response producing characteristic fluid-filled vesicles arranged in bands following dermatome distributions. Management includes antiviral medications like acyclovir, valacyclovir, or famciclovir started ideally within 72 hours of rash onset to reduce duration and severity. Supportive care includes pain management with topical lidocaine patches, systemic analgesics, antihistamines for itching, and wet compresses for comfort.

Why It Matters

Shingles affects approximately 1 million Americans annually, with the CDC estimating that 99% of Americans over 30 have been exposed to varicella-zoster virus. Healthcare costs exceed $500 million yearly for shingles treatment and complications, including lost work productivity valued at approximately $70 million. The condition causes significant morbidity with 5-10% of patients experiencing long-term complications like postherpetic neuralgia that impairs quality of life. Approximately 1 in 10 people who get shingles will develop postherpetic neuralgia, with pain sometimes persisting for months or years.

Shingles has significant applications across multiple healthcare sectors and industries involved in prevention and treatment. Pharmaceutical companies including Merck (Shingrix vaccine developer), GlaxoSmithKline, and Janssen develop and manufacture antiviral medications and vaccines, generating substantial revenue from a preventable disease. Health insurance companies and government healthcare programs allocate billions annually for shingles-related medical expenses, making prevention economically attractive. Telemedicine providers and dermatology practices increasingly offer shingles consultations, recognizing the disease's prevalence and the need for rapid diagnosis and treatment.

Future trends in shingles management include development of alternative vaccines with improved efficacy and lower adverse event profiles, expansion of vaccination coverage beyond age 50 to younger immunocompromised populations, and research into novel antivirals with better tissue penetration. Emerging therapies like therapeutic vaccines designed to boost cellular immunity in people with latent VZV infection show promise in clinical trials. Artificial intelligence applications in dermatology may enable faster diagnosis through image recognition of characteristic rash patterns. Personalized medicine approaches may eventually identify individuals at highest risk for severe disease or complications, allowing targeted interventions.

Common Misconceptions

Myth: You can catch shingles from someone with shingles. Reality: Shingles itself is not contagious; however, someone with active shingles can transmit varicella-zoster virus to people who have never had chickenpox, causing them to develop chickenpox, not shingles. The virus is spread through respiratory droplets or direct contact with shingles lesions. A person can only develop shingles if they have previously had chickenpox or received the varicella vaccine.

Myth: Shingles is caused by chickenpox exposure during adulthood. Reality: Shingles results from reactivation of the virus acquired during a prior chickenpox infection, typically from childhood. The virus remains dormant in nerve tissue for decades before reactivating, usually triggered by immune system decline rather than new exposure. Even people vaccinated against chickenpox can theoretically develop shingles, though the risk is significantly lower than in those who had natural chickenpox infection.

Myth: Young, healthy people don't need to worry about shingles. Reality: While shingles primarily affects older adults and immunocompromised individuals, it can occur at any age in people with weakened immunity, including those with HIV/AIDS, autoimmune conditions, or taking immunosuppressive medications. Young transplant recipients, cancer patients undergoing chemotherapy, and people with severe stress or illness can develop shingles. The CDC recommends vaccination for all adults age 50 and older, acknowledging that this population has the highest absolute risk.

Common Misconceptions